Importantly, our human postmortem data suggest that markers of SA activity are increased in the hippocampus and PFC of AD brains (i.e., decreased SKA2 expression along with enhanced SEC22B to SNAP29 binding). The gene discussed is SNAP29; the disease is Alzheimer disease.